NYSE:RCUS 14 December 2025

Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens

Arcus Biosciences shares slid 9.3% to $21.05 in afternoon trading on Thursday, after earlier touching $22.70. The stock hit a session low of $21.02.

8 January 2026

NYSE:RCUS·Pharmaceutical Industry·Stock Market

Arcus Biosciences (RCUS) Stock News, Forecasts and Analyst Targets — Dec. 14, 2025 Update

Arcus Biosciences, Inc. is ending the weekend under a bright—and volatile—spotlight after a major clinical-program reset triggered a sharp Friday selloff. As of Sunday, December 14, 2025, the last reported close was $21.53, down 14.36% from the prior session, reflecting investor repricing after Arcus and partner Gilead halted a pivotal upper-GI cancer study. StockAnalysis

14 December 2025